CTOs on the Move

Vividion

www.vividion.com

 
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.vividion.com
  • 5820 Nancy Ridge Drive
    San Diego, CA USA 92121
  • Phone: 858.345.4690

Executives

Name Title Contact Details

Funding

Vividion raised $50M on 02/02/2017
Vividion raised $101M on 03/05/2018
Vividion raised $82M on 04/30/2019
Vividion raised $135M on 02/24/2021

Similar Companies

Entegrion

Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Celula Inc

Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

InVitria

InVitria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.